Gilead Sciences (United States)

Recent papers from Gilead Sciences (United States)

1. Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesisNature Metabolism · 2020
2. Associations Between Liver Biomarkers and Clinical Outcomes in Patients With Primary Sclerosing Cholangitis: A Retrospective Real‐World StudyLiver international communications. · 2026
3. MHCII+ cancer-associated fibroblasts promote antitumor immunity in pancreatic cancer2026
4. Relationship of Biochemical Response as Surrogate Endpoints with Long-Term Outcomes in Primary Biliary Cholangitis: A Global Systematic Review and Meta-AnalysisJournal of health economics and outcomes research · 2026
5. Cancer cell adaptations along a proliferation-robustness axis drive TME pro-tumor phenotypes2026
6. Real‐World Effectiveness and Safety of Sofosbuvir‐Based Therapy in Chinese Children and Adolescents With Chronic HCV Infection: A Retrospective Multicentre StudyJournal of Viral Hepatitis · 2026
7. Sexualized drug use and high-risk behaviors among men who have sex with men, transgender women, and gender-diverse individuals in AndalusiaInternational Journal of STD & AIDS · 2026
8. The Bi-directional Effects of Gender-Affirming Hormone Therapy and Preexposure Prophylaxis in Transgender IndividualsOpen Forum Infectious Diseases · 2026
9. Rare and Novel Hepatitis C Virus Genotype Subtypes and Response to Sofosbuvir/Velpatasvir in A5360 ( MINMON ) Clinical TrialJournal of Viral Hepatitis · 2026
10. Altered Na+Currents in Atrial FibrillationJournal of the American College of Cardiology · 2010
11. Methodological considerations for indirect treatment comparisons of HIV incidence for long-acting injectable pre-exposure prophylaxisJournal of Comparative Effectiveness Research · 2026
12. Engineered TYK2 dependence enables myeloid-selective IL-10 receptor agonismNature · 2026
13. The Economic Burden of HDV in Italy: Evaluating the Potential Impact and Effects of Bulevirtide for Chronic HDV InfectionClinical Drug Investigation · 2026
14. Long-Term Hepatic Safety of Ambrisentan in Patients With Pulmonary Arterial HypertensionJournal of the American College of Cardiology · 2012
15. Real-World First-Line Treatment Characteristics and Physician Drivers in Advanced/Metastatic Non–Small Cell Lung Cancer, PD-L1 ≥ 50%, and without Actionable Genomic AlterationsOncology and Therapy · 2026
16. Synthetic Development and Scale-Up of the Aminoindazole Fragment of LenacapavirOrganic Process Research & Development · 2026
17. Missed opportunities for PrEP among the partners of people newly initiated in HIV care in western TanzaniaJAIDS Journal of Acquired Immune Deficiency Syndromes · 2026
18. Changing to a once-a-day single pill of bictegravir/lenacapavir from complex HIV treatment: a plain language summary of the ARTISTRY-1 study up to 1 yearFuture Virology · 2026
19. A human single-cell atlas identifies OLR1+ scar-associated macrophages as a potential therapeutic target for chronic liver diseaseNature Genetics · 2026
20. A Model‐Robust G‐Computation Method for Analyzing Hybrid Control Studies Without Assuming ExchangeabilityStatistics in Medicine · 2026